Artivion (NYSE:AORT) Announces Earnings Results, Misses Estimates By $0.51 EPS

Artivion (NYSE:AORT) posted its quarterly earnings data on Monday. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.51), reports. The company had revenue of $97.31 million for the quarter, compared to the consensus estimate of $100.82 million. Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. Artivion updated its FY 2025 guidance to EPS.

Artivion Price Performance

Shares of NYSE:AORT traded down $2.85 during midday trading on Tuesday, reaching $25.00. The company’s stock had a trading volume of 375,415 shares, compared to its average volume of 351,872. The business’s fifty day simple moving average is $29.75 and its 200-day simple moving average is $27.83. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. Artivion has a fifty-two week low of $18.38 and a fifty-two week high of $32.33. The company has a market capitalization of $1.05 billion, a P/E ratio of -1,248.00 and a beta of 1.75.

Insider Buying and Selling

In related news, VP Andrew M. Green sold 7,618 shares of the business’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $30.00, for a total transaction of $228,540.00. Following the completion of the sale, the vice president now directly owns 33,503 shares of the company’s stock, valued at $1,005,090. The trade was a 18.53 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CAO Amy Horton sold 4,329 shares of the firm’s stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $29.66, for a total transaction of $128,398.14. Following the completion of the transaction, the chief accounting officer now directly owns 135,660 shares in the company, valued at approximately $4,023,675.60. The trade was a 3.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 20,017 shares of company stock worth $600,007 in the last 90 days. Corporate insiders own 8.10% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Needham & Company LLC reduced their price objective on shares of Artivion from $34.00 to $32.00 and set a “buy” rating for the company in a report on Tuesday. Oppenheimer raised their target price on Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. JMP Securities restated a “market outperform” rating and issued a $33.00 target price on shares of Artivion in a research note on Tuesday, December 10th. Finally, Stifel Nicolaus dropped their target price on shares of Artivion from $33.00 to $30.00 and set a “buy” rating for the company in a research report on Tuesday. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $31.40.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.